tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

enGene Holdings Inc

ENGN
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
2.410USD
+0.130+5.70%
์ข…๊ฐ€ย 11-13 16:00๏ผˆET๏ผ‰
161.52M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM

enGene Holdings Inc ์ •๋ณด ํšŒ์‚ฌ

enGene Holdings Inc. is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. The Companyโ€™s lead program is detalimogene voraplasmid, (detalimogene) for patients with non-muscle invasive bladder cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase II study, which includes a cohort studying detalimogene in Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (Cis). Detalimogene is being developed through its proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. The Company is developing non-viral genetic medicines based on its DDX gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

enGene Holdings Inc ํ”„๋กœํ•„

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ ENGN
ํšŒ์‚ฌ ์ด๋ฆ„enGene Holdings Inc
์ƒ์žฅ์ผDec 10, 2021
CEOCooper (Ronald Harold Wilfred)
์ง์› ์ˆ˜56
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒDec 10
์ฃผ์†Œ4868 Rue Levy, Suite 220
๋„์‹œSAINT-LAURENT
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€Canada
์šฐํŽธ ๋ฒˆํ˜ธH4R 2P1
์ „ํ™”15143324888
์›น์‚ฌ์ดํŠธhttps://engene.com/
์ข…๋ชฉ ์ฝ”๋“œ ENGN
์ƒ์žฅ์ผDec 10, 2021
CEOCooper (Ronald Harold Wilfred)

enGene Holdings Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Katherine Chan, M.D.
Dr. Katherine Chan, M.D.
Executive Director - Urology Clinical Lead
Executive Director - Urology Clinical Lead
--
--
Ms. Amy Pott
Ms. Amy Pott
Chief Global Commercialization Officer
Chief Global Commercialization Officer
--
--
Dr. William Grossman, M.D., Ph.D.
Dr. William Grossman, M.D., Ph.D.
Interim Chief Medical Officer, Director
Interim Chief Medical Officer, Director
--
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matthew Boyd
Mr. Matthew Boyd
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Ms. Jill Buck
Ms. Jill Buck
Chief Development Officer
Chief Development Officer
--
--
Mr. Constantine Chinoporos
Mr. Constantine Chinoporos
Interim Chief Business Officer
Interim Chief Business Officer
--
--
Mr. Jason G. Duncan
Mr. Jason G. Duncan
Chief Legal and Administrative Officer
Chief Legal and Administrative Officer
--
--
Dr. Erik Goluboff, M.D.
Dr. Erik Goluboff, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Joan Connolly
Ms. Joan Connolly
Chief Technology Officer
Chief Technology Officer
--
--
๋” ๋ณด๊ธฐ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Katherine Chan, M.D.
Dr. Katherine Chan, M.D.
Executive Director - Urology Clinical Lead
Executive Director - Urology Clinical Lead
--
--
Ms. Amy Pott
Ms. Amy Pott
Chief Global Commercialization Officer
Chief Global Commercialization Officer
--
--
Dr. William Grossman, M.D., Ph.D.
Dr. William Grossman, M.D., Ph.D.
Interim Chief Medical Officer, Director
Interim Chief Medical Officer, Director
--
--
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Matthew Boyd
Mr. Matthew Boyd
Chief Regulatory Officer
Chief Regulatory Officer
--
--
Ms. Jill Buck
Ms. Jill Buck
Chief Development Officer
Chief Development Officer
--
--

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

enGene Holdings Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
enGene Holdings Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค: Mr. Wouter Joustra
tradingkey.logo
์œ„ํ—˜ ๊ฒฝ๊ณ : ์ €ํฌ ์›น์‚ฌ์ดํŠธ์™€ ๋ชจ๋ฐ”์ผ ์•ฑ์€ ํŠน์ • ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ผ๋ฐ˜์ ์ธ ์ •๋ณด๋งŒ์„ ์ œ๊ณตํ•ฉ๋‹ˆ๋‹ค. Finsights๋Š” ์žฌ์ •์  ์กฐ์–ธ์ด๋‚˜ ํˆฌ์ž ์ƒํ’ˆ์— ๋Œ€ํ•œ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜์ง€ ์•Š์œผ๋ฉฐ, ์ด๋Ÿฌํ•œ ์ •๋ณด ์ œ๊ณต์ด Finsights๊ฐ€ ๊ธˆ์œต ์กฐ์–ธ์ด๋‚˜ ์ถ”์ฒœ์„ ์ œ๊ณตํ•˜๋Š” ๊ฒƒ์œผ๋กœ ํ•ด์„๋˜์–ด์„œ๋Š” ์•ˆ ๋ฉ๋‹ˆ๋‹ค.
ํˆฌ์ž ์ƒํ’ˆ์€ ํˆฌ์ž ์›๊ธˆ ์†์‹ค์„ ํฌํ•จํ•œ ์ƒ๋‹นํ•œ ํˆฌ์ž ์œ„ํ—˜์— ๋…ธ์ถœ๋˜์–ด ์žˆ์œผ๋ฉฐ, ๋ชจ๋“  ์‚ฌ๋žŒ์—๊ฒŒ ์ ํ•ฉํ•˜์ง€ ์•Š์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ํˆฌ์ž ์ƒํ’ˆ์˜ ๊ณผ๊ฑฐ ์„ฑ๊ณผ๋Š” ๋ฏธ๋ž˜ ์„ฑ๊ณผ๋ฅผ ๋ณด์žฅํ•˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.
Finsights๋Š” ์ œ3์ž ๊ด‘๊ณ ์ฃผ๋‚˜ ์ œํœด์‚ฌ๊ฐ€ ์ €ํฌ ์›น์‚ฌ์ดํŠธ๋‚˜ ๋ชจ๋ฐ”์ผ ์•ฑ ๋˜๋Š” ๊ทธ ์ผ๋ถ€์— ๊ด‘๊ณ ๋ฅผ ๊ฒŒ์žฌํ•˜๊ฑฐ๋‚˜ ์ „๋‹ฌํ•  ์ˆ˜ ์žˆ๋„๋ก ํ—ˆ์šฉํ•  ์ˆ˜ ์žˆ์œผ๋ฉฐ, ์‚ฌ์šฉ์ž๊ฐ€ ๊ด‘๊ณ ์™€ ์ƒํ˜ธ์ž‘์šฉํ•˜๋Š” ๋ฐฉ์‹์— ๋”ฐ๋ผ ์ด๋“ค๋กœ๋ถ€ํ„ฐ ๋ณด์ƒ์„ ๋ฐ›์„ ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
ยฉ ์ €์ž‘๊ถŒ: FINSIGHTS MEDIA PTE. LTD. ๋ชจ๋“  ๊ถŒ๋ฆฌ ๋ณด์œ